World Health Organization Emerging and other Communicable Diseases, Surveillance and Control

Transcription

1 WHO/EMC/ZDI/98.10 Use of Quinolones in Food Animals and Potential Impact on Human Health Report of a WHO Meeting Geneva, Switzerland 2-5 June 1998 World Health Organization Emerging and other Communicable Diseases, Surveillance and Control This document has been downloaded from the WHO/EMC Web site. The original cover pages and lists of participants are not included. See for more information.

2 World Health Organization 1998 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the ressponsibility of those authors. The mention of specific companies or specific manufacturers' products does no imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

3

4

5

6

7

8

9

10

11 Table 1 Proprietary quinolones currently licensed for use in animals Generic name Trade name cattle swine chickens turkeys Dogs cats fish enrofloxacin Baytril X X X X X X X a danofloxacin Advocin, Advocid X X X norfloxacin Quinabic X X ofloxacin Oxaldin X X ciprofloxacin generic X X sarafloxacin Floxasol Saraflox Sarafin X X X orbifloxacin Victas Orbax X X X X marbofloxacin Marbocyl X X X X flumequine many X X X X oxolinic acid many X X X X difloxacin Vetequinon Dicural X X X X a Baytril is not licensed for this use but generic products are available in some countries

12 Table 2 Quinolones licensed for use in food animals by region of the world Region Livestock Poultry Pet animals Fish Europe flumequine, marbofloxacin, danofloxacin difloxacin, flumequine, oxolinic acid difloxacin, marbofloxacin sarafloxacin, (oxolinic acid) a USA none sarafloxacin Japan Asia Latin America danofloxacin, orbifloxacin, difloxacin, oxolinic acid danofloxacin, ciprofloxacin ciprofloxacin, danofloxacin, norfloxacin, (flumequine) danofloxacin, ofloxacin, vebufloxacin, oxolinic acid ciprofloxacin, danofloxacin, ofloxacin, flumequine, norfloxacin, oxolinic acid, (sarafloxacin) ciprofloxacin, danofloxacin, norfloxacin, (flumequine, oxolinic acid) difloxacin, orbifloxacin orbifloxacin enrofloxacin enrofloxacin none Canada enrofloxacin b enrofloxacin Australia none none enrofloxacin none South Africa danofloxacin danofloxacin, norfloxacin a Substances in parentheses are in limited use. b Voluntarily withdrawn from the market in enrofloxacin oxolinic acid oxolinic acid flumequine oxolinic acid

13 Table 3 Indications of use and formulations of quinolones for treatment of infection in animals Animal species Licensed use Major bacteria Formulations cattle respiratory, enteric Pasteurella spp., Haemophilus somnus, Mycoplasma bovis swine respiratory, enteric, mastitis/metritis Pasteurella spp., Actinobacillus pleuropneumoniae, Mycoplasma, E. coli broilers respiratory, enteric E. coli, Mycoplasma, Pasteurella, Salmonella turkeys respiratory, enteric E. coli, Mycoplasma, Pasteurella, Salmonella fish dogs cats generalised conditions (septicemia), skin/ulcers skins/wounds, urinary tract, respiratory skins/wounds, urinary tract, respiratory Aeromonas hydrophila Vibrio spp. S. intermedius, E. coli, Pasteurella S. intermedius, E. coli, Pasteurella injectable, bolus injectable, oral solution, feed medication oral (water medication) oral (water medication) oral (feed medication), water bath tablets, injectable tablets, injectable

14

15

16

17

18

19

20